Bibliography
- Wills-Karp M. Interleukin-13 in asthma pathogenesis. Curr Allergy Asthma Rep 2004;4(2):123-31
- GINA Report, Global Strategy for Asthma Management and Prevention- December 2011 update. 2012
- Corren J, Lemanske RF, Hanania NA, Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365(12):1088-98
- Hodsman GP, Ashman C, Cahn A, A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics. Br J Clin Pharmacol 2012; [Epub ahead of print]
- Piper E, Brightling C, Niven R, A phase 2 placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2012; [Epub ahead of print]
- GINA Report, Global Strategy for Asthma Management and Prevention. GINA Report, Global Strategy for Asthma Management and Prevention 2009
- Korn S, Schumann C, Kropf C, Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma. Ann Allergy Asthma Immunol 2010;105(4):313-19
- Blanchard C, Mishra A, Saito-Akei H, Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). Clin Exp Allergy 2005;35(8):1096-103
- May RD, Monk PD, Cohen ES, Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma. Br J Pharmacol 2012;166(1):177-93
- Berry MA, Parker D, Neale N, Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. J Allergy Clin Immunol 2004;114(5):1106-9